D
Dean Wilkie
Researcher at Bayer HealthCare Pharmaceuticals
Publications - 8
Citations - 6100
Dean Wilkie is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Matrix metalloproteinase & Sorafenib. The author has an hindex of 8, co-authored 8 publications receiving 5683 citations.
Papers
More filters
Journal ArticleDOI
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Scott Wilhelm,Christopher A. Carter,LiYa Tang,Dean Wilkie,Angela McNabola,Hong Rong,Charles Chen,Xiaomei Zhang,Patrick Vincent,Mark McHugh,Yichen Cao,Jaleel Shujath,Susan Gawlak,Deepa Eveleigh,Bruce Rowley,Li Liu,Lila Adnane,Mark Lynch,Daniel Auclair,Ian W. Taylor,Rich Gedrich,Andrei Voznesensky,Bernd Riedl,Leonard Post,Gideon Bollag,Pamela A. Trail +25 more
TL;DR: Data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis.
Journal ArticleDOI
Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5
Li Liu,Yichen Cao,Charles Chen,Xiaomei Zhang,Angela McNabola,Dean Wilkie,Scott Wilhelm,Mark Lynch,Christopher A. Carter +8 more
TL;DR: The results suggest that the antitumor activity of sorafenib in HCC models may be attributed to inhibition of tumor angiogenesis (VEGFR and PDGFR) and direct effects on tumor cell proliferation/survival (Raf kinase signaling-dependent and signaling-independent mechanisms).
Journal ArticleDOI
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Yong S. Chang,Jalila Adnane,Pamela A. Trail,Joan Levy,Arris J. Henderson,Dahai Xue,Elizabeth Bortolon,Marina Ichetovkin,Charles Chen,Angela McNabola,Dean Wilkie,Christopher A. Carter,Ian C. A. Taylor,Mark Lynch,Scott Wilhelm +14 more
TL;DR: The results show the ability of sorafenib to potently inhibit the growth of both ectopic- and orthotopically-implanted Renca and 786-O tumor models, which is a highly vascularized and treatment-resistant tumor.
Journal ArticleDOI
Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma
Christine Elser,Lillian L. Siu,Eric Winquist,Mark Agulnik,Gregory R. Pond,Soo Chin,Peggy Francis,Robin Cheiken,James Elting,Angela McNabola,Dean Wilkie,Oana Petrenciuc,Eric Chen +12 more
TL;DR: Sorafenib was well tolerated and had modest anticancer activity comparable to monotherapy with other targeted agents in this group of patients, and further development in combination with radiation or other agents may be warranted.
Journal ArticleDOI
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
Ningshu Liu,Bruce R. Rowley,Cathy O. Bull,Claudia Schneider,Andrea Haegebarth,Christoph Schatz,Paul R. Fracasso,Dean Wilkie,Martin F. Hentemann,Scott Wilhelm,William J. Scott,Dominik Mumberg,Karl Ziegelbauer +12 more
TL;DR: BAY 80-6946 is a promising agent with differential pharmacologic and pharmacokinetic properties for the treatment of PI3K-dependent human tumors and induced 100% complete tumor regression when dosed as a single agent every second day in rats bearing HER2-amplified and PIK3CA-mutated KPL4 breast tumors.